P&G Throws Weight Behind Consumer Growth After Shedding Pharma
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble faces several options - and some potential challenges - to grow its OTC portfolio using the resources gained in the sale of its prescription drug business
You may also be interested in...
P&G's OTC Market Direction Steered By Consumers' Turn To Self-Care Solutions
Firm scans health care market for OTC drug properties meeting consumers’ growing demand for non-Rx products, says CFO Jon Moeller. He says P&G is well-positioned to "brand-build" acquired assets given its distribution network in oral, personal and feminine care, and its cost-cutting capabilities.
P&G's OTC Market Direction Steered By Consumers' Turn To Self-Care Solutions
Firm scans health care market for OTC drug properties meeting consumers’ growing demand for non-Rx products, says CFO Jon Moeller. He says P&G is well-positioned to "brand-build" acquired assets given its distribution network in oral, personal and feminine care, and its cost-cutting capabilities.
New Chapter Taps Into P&G Product Development Capacity
Six months after becoming a wholly owned subsidiary of Procter & Gamble, dietary supplement firm New Chapter is taking advantage of its parent company’s resources in innovation, ingredient sourcing, clinical trials and packaging, says New Chapter VP Graham Rigby.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: